To observe the recent clinical effects and the side effects of CE and EP regimens for small cell lung cancer (SCLC) ,52 patients were randomized into CE group (carboplatin and etoposide) and EP group (cisplatin and etoposide) according to the hospital order, to be treated for 2 cycles. The recent clinical effects of two groups had no significance ( P ＞ 0. 05 ), CE goup with CR 6 cases, PR 14 cases and the total effectual 20 cases (76.9％); EP group with CR5 cases, PR 13 cases and the total effectual 18 cases (69.2％). Two groups had no significance on the side effects of above 2 degrees gastrointestinal reaction and myelosuppression, both groups patients were tolerable. It is conclused that CE and EP regimens are effective for small cell lung cancer, no significance on the recent clinical effects, the side effects are tolerable. They might be considered as relevant regimens in initial patients with small cell lung cancer.%为观察CE与EP方案治疗小细胞肺癌的近期疗效和毒副反应,对52例小细胞肺癌患者按住院先后顺序,随机分为CE组(卡铂+足叶乙甙)和EP组(顺铂+足叶乙甙),化疗2周期后评价疗效.结果近期疗效方面,CE组CR6例,PR14例,总有效20例(76.9%);EP组CR5例,PR13例,总有效18例(69.2%),两组比较无差别(P>0.05).在毒副反应方面,CE与EP两组发生Ⅱ度以上的胃肠道反应及骨髓抑制无差别,患者均能耐受.说明CE与EP方案治疗小细胞肺癌均有效,且近期疗效无差别,毒副反应均能耐受,均可作为小细胞肺癌一线化疗方案.
展开▼
